Centre for Rheumatology and Connective Tissue Disease

Key Publications

1 Black CM, Silman AJ, Herrick AL, Denton CP, Wilson H, Newman J, Pompon L, Shi-wen X Interferon-a does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomised, double-blind, placebo-controlled trial. Arthritis Rheum . 1999 Feb: 42 (2):299-305
2 Abraham DJ, Shiwen X, Black CM, Sa S, Xu Y, Leask A. Tumor necrosis factor alpha suppresses the induction of connective tissue growth factor by transforming growth factor-beta in normal and scleroderma fibroblasts. J Biol Chem . 2000 May 19; 275 (20):15220-5
3 Holmes A, Abraham DJ, Sa S, Shiwen X, Black CM, Leask A CTGF and SMADs, maintenance of scleroderma phenotype is independent of SMAD signalling. J Biol Chem . 2001 Apr 6; 276 (14):10594-601
4 Denton CP, Zheng B, Rabe C, Zhang Z, Eberspaecher H, Black CM, de Crombrugghe B
Activation of a fibroblast-specific enhancer of the prosa2(I) collagen gene in tight-skin mice. Arthritis Rheum . 2001 Mar; 44 (3):712-22
5 Stratton R, Shiwen X, Martini G, Holmes A, Leask A, Haberberger T, Martin GR, Black CM, Abraham D Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients. J Clin Invest . 2001 Jul; 108 (2):241-50.